Therapeutic effect of vitamin K1 combined with meropenem on the treatment of pertussis syndrome

Chen,Wenxin; Guo,Yufeng

doi:10.3892/etm.2019.7586

Therapeutic effect of vitamin K1 combined with meropenem on the treatment of pertussis syndrome

Authors:
- Wenxin Chen
- Yufeng Guo
View Affiliations

Affiliations: Department of Pediatric Internal Medicine, The Second People's Hospital of Liaocheng, Liaocheng, Shandong 252600, P.R. China, Department of Cardiothoracic Surgery, The Second People's Hospital of Liaocheng, Liaocheng, Shandong 252600, P.R. China
Published online on: May 16, 2019 https://doi.org/10.3892/etm.2019.7586
Pages: 642-646
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Clinical efficacy of vitamin K1 combined with meropenem on the treatment of pertussis syndrome was evaluated. Clinical data of 170 children with pertussis syndrome treated in the Second People's Hospital of Liaocheng from March 2015 to March 2017 were collected. Of these, 87 patients who were treated with vitamin K1 combined with meropenem were regarded as the experiment group. A total of 83 patients who were treated with meropenem alone were regarded as the control group. Both groups were treated with anti‑infective, respiratory support, antispasmodic, expectorant and other basic treatments. The therapeutic effects, duration of spasmodic cough, length of hospitalization, antipyretic time, duration of voice disappearance and healing time were observed between the two groups. The duration of spasmodic cough and length of hospitalization in the experiment were lower than the control group, and the difference was statistically significant between the groups (P<0.05). The explicit efficiency (51.72%) and total effective efficiency (99.55%) in the experiment group were significantly higher than the explicit efficiency (36.14%) and total effective efficiency (78.31%) in the control group. There was a statistically significant difference between the groups (P<0.05). The voice disappearance time and healing time in the experiment group were significantly shorter than the control group, and there was a statistically significant difference between the groups (P<0.05). The antipyretic time in the experiment group was lower than that of the control group, the difference between the groups was not statistically significant (P>0.05). The treatment with vitamin K1 and meropenem has a significant effect in relieving pediatric pertussis syndrome, it can shorten the duration of spasmodic cough, antipyretic time, duration of voice disappearance and length of hospitalization in children with pertussis syndrome, and improve the efficacy clinically.

View Figures

View References

1	Ferronato AE, Gilio AE and Vieira SE: Respiratory viral infections in infants with clinically suspected pertussis. J Pediatr (Rio J). 89:549–553. 2013. View Article : Google Scholar : PubMed/NCBI
2	Burr JS, Jenkins TL, Harrison R, Meert K, Anand KJ, Berger JT, Zimmerman J, Carcillo J, Dean JM, Newth CJ, et al Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Collaborative Pediatric Critical Care Research Network (CPCCRN), : The Collaborative Pediatric Critical Care Research Network Critical Pertussis Study: collaborative research in pediatric critical care medicine. Pediatr Crit Care Med. 12:387–392. 2011. View Article : Google Scholar : PubMed/NCBI
3	Craig-Mylius KA and Weiss AA: Antibacterial agents and release of periplasmic pertussis toxin from Bordetella pertussis. Antimicrob Agents Chemother. 44:1383–1386. 2000. View Article : Google Scholar : PubMed/NCBI
4	Hozbor D, Mooi F, Flores D, Weltman G, Bottero D, Fossati S, Lara C, Gaillard ME, Pianciola L, Zurita E, et al: Pertussis epidemiology in Argentina: trends over 2004–2007. J Infect. 59:225–231. 2009. View Article : Google Scholar : PubMed/NCBI
5	Nelson KE, Gavitt F, Batt MD, Kallick CA, Reddi KT and Levin S: The role of adenoviruses in the pertussis syndrome. J Pediatr. 86:335–341. 1975. View Article : Google Scholar : PubMed/NCBI
6	Guiso N, Wirsing von König CH, Forsyth K, Tan T and Plotkin SA: The Global Pertussis Initiative: report from a round table meeting to discuss the epidemiology and detection of pertussis, Paris, France, 11–12 January 2010. Vaccine. 29:1115–1121. 2011. View Article : Google Scholar : PubMed/NCBI
7	Cherry JD: Epidemic pertussis in 2012 - the resurgence of a vaccine-preventable disease. N Engl J Med. 367:785–787. 2012. View Article : Google Scholar : PubMed/NCBI
8	Salimi A, Eybagi S, Seydi E, Naserzadeh P, Kazerouni NP and Pourahmad J: Toxicity of macrolide antibiotics on isolated heart mitochondria: a justification for their cardiotoxic adverse effect. Xenobiotica. 46:82–93. 2016. View Article : Google Scholar : PubMed/NCBI
9	Shearer MJ: Vitamin K. Lancet. 345:229–234. 1995. View Article : Google Scholar : PubMed/NCBI
10	Shearer MJ: Role of vitamin K and Gla proteins in the pathophysiology of osteoporosis and vascular calcification. Curr Opin Clin Nutr Metab Care. 3:433–438. 2000. View Article : Google Scholar : PubMed/NCBI
11	De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, et al: Vitamin K antagonists in heart disease: Current status and perspectives (Section III). Position paper of the ESC Working Group on Thrombosis-Task force on anticoagulants in heart disease. Thromb Haemost. 110:1087–1107. 2013. View Article : Google Scholar : PubMed/NCBI
12	Wang Y: New materia medica project: synthetic biology based bioactive metabolites research in medicinal plant. Sheng Wu Gong Cheng Xue Bao. 33:478–485. 2017.(In Chinese). PubMed/NCBI
13	Koklu E, Taskale T, Koklu S and Ariguloglu EA: Anaphylactic shock due to vitamin K in a newborn and review of literature. J Matern Fetal Neonatal Med. 27:1180–1181. 2014. View Article : Google Scholar : PubMed/NCBI
14	Nowak-Göttl U, Dietrich K, Schaffranek D, Eldin NS, Yasui Y, Geisen C and Mitchell LG: In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes. Blood. 116:6101–6105. 2010. View Article : Google Scholar : PubMed/NCBI
15	Per H, Arslan D, Gümüş H, Coskun A and Kumandaş S: Intracranial hemorrhages and late hemorrhagic disease associated cholestatic liver disease. Neurol Sci. 34:51–56. 2013. View Article : Google Scholar : PubMed/NCBI
16	Rhomberg PR and Jones RN; MYSTIC Program (USA) Study Group, : Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagn Microbiol Infect Dis. 47:365–372. 2003. View Article : Google Scholar : PubMed/NCBI
17	Abo El Sooud K: Plasma pharmacokinetics and urine concentrations of meropenem in ewes. J Vet Pharmacol Ther. 27:27–30. 2004. View Article : Google Scholar : PubMed/NCBI
18	Forsyth KD, Wirsing von Konig CH, Tan T, Caro J and Plotkin S: Prevention of pertussis: recommendations derived from the second Global Pertussis Initiative roundtable meeting. Vaccine. 25:2634–2642. 2007. View Article : Google Scholar : PubMed/NCBI
19	Black RE, Morris SS and Bryce J: Where and why are 10 million children dying every year? Lancet. 361:2226–2234. 2003. View Article : Google Scholar : PubMed/NCBI
20	Tan TQ and Gerbie MV: Pertussis, a disease whose time has come: What can be done to control the problem? Obstet Gynecol. 122:370–373. 2013. View Article : Google Scholar : PubMed/NCBI
21	Galdi E and Moscato G: Pertussis in the aetiology of chronic cough in adults. Monaldi Arch Chest Dis. 57:229–230. 2002.PubMed/NCBI
22	Wang J, Yang Y, Li J, Mertsola J, Arvilommi H, Shen X and He Q: Infantile pertussis rediscovered in China. Emerg Infect Dis. 8:859–861. 2002. View Article : Google Scholar : PubMed/NCBI
23	Centers for Disease Control Prevention (CDC), . Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. MMWR Morb Mortal Wkly Rep. 60:13–15. 2011.PubMed/NCBI
24	Horiba K, Nishimura N, Gotoh K, Kawaguchi M, Takeuchi S, Hattori F, Isaji M, Okai Y, Hosono H, Takemoto K, et al: Clinical manifestations of children with microbiologically confirmed pertussis infection and antimicrobial susceptibility of isolated strains in a regional hospital in Japan, 2008–2012. Jpn J Infect Dis. 67:345–348. 2014. View Article : Google Scholar : PubMed/NCBI
25	Benzakour O, Gely A, Lara R and Coronas V: Gas-6 and protein S: Vitamin K-dependent factors and ligands for the TAM tyrosine kinase receptors family. Med Sci (Paris). 23:826–833. 2007.(In French). View Article : Google Scholar : PubMed/NCBI
26	Ateskan U, Mas MR, Yasar M, Deveci S, Babaoglu E, Comert B, Mas NN, Doruk H, Tasci I, Ozkomur ME, et al: Deferoxamine and meropenem combination therapy in experimental acute pancreatitis. Pancreas. 27:247–252. 2003. View Article : Google Scholar : PubMed/NCBI